Schwazze

Schwazze (Medicine Man Tech) carries a Neutral rating, with a composite score of 47 out of 100 and a conviction reading of 2 of 5. Four pillars feed the composite in fixed weights (35/25/25/15 for fundamentals, regulatory, market, and editorial), and no clause of the score is hidden from the reader. Fundamentals carries this profile, printing 56 and setting the ceiling on the composite. The editorial pillar sits at 30, and is the main drag on the composite.

The scoring inputs are concrete: reported revenue growth of 2.0 percent year over year, an operating margin of -6.3 percent, a jurisdictional posture reading of 50. Together they explain most of the pillar mix. The scoring pipeline pulls only from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage, and each pillar exposes its own inputs. This lets Schwazze (Medicine Man Tech) be lined up against the US operator peer set on identical inputs, with refresh cadence tied directly to primary-source ingest.

The next quarterly release stands as the primary catalyst, since fundamentals drive 56 of the composite. A revenue print above the trailing four-quarter average combined with a stable operating margin would justify a step toward the upper band edge, while a miss on either would erode the Neutral anchor.